Omnitrope Injection 15 Mg/1.5 ML
Generic Name : Somatropin
What is Omnitrope?
Omnitrope (Somatropin) is a form of human growth hormone important for the growth of bones and muscles. Omnitrope is used to treat growth failure in children and adults who lack natural growth hormone. This includes people with with Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes.
Omnitrope is a type of human growth hormone used to treat growth failure in kids and grown-ups who need common growth hormone, Omnitrope 15 mg in those with ongoing kidney failure, Noonan disorder, Turner syndrome, Omnitrope HGH help short height upon entering the world with no make up for lost time growth, and different causes. Omnitrope price in india low at Yourmedikart.
What is Omnitrope Used For?
Omnitrope (Somatropin [rDNA origin] infusion) is a type of human growth hormone used to treat growth failure in kids and grown-ups who need common growth hormone, and in those with ongoing kidney failure, Noonan disorder, Turner syndrome, short height upon entering the world with no make up for lost time growth, and different causes. Omnitrope injection available at Yourmedikart. Omnitrope online available in india at best price. Omnitrope price will get best at when you buy Omnitrope buy online.
Medicinal Product Name
Omnitrope 15 mg/1.5 ml solution for injection in cartridge
Each ML of solution contains 10 mg of Somatropin (corresponding to 30 IU)
One cartridge contains 1.5 ml corresponding to 15 mg Somatropin (45 IU).
Produced in Escherichia coli by recombinant DNA technology.
Babies, youngsters and teenagers
– Growth disturbance influence due to insufficient secretion of growth hormone (growth hormone deficiency, GHD).
– Growth disturbance influence related with Turner syndrome.
– Growth disturbance related with chronic renal insufficiency.
– Growth disturbance (current tallness standard deviation score (SDS) < – 2.5 and parental changed stature SDS < – 1) in short kids/youths conceived little for gestational age (SGA), with a birth weight and additionally length below – 2 standard deviation (SD), who failed to show catch-up growth (stature speed (HV) SDS < 0 during the most recent year) by 4 years old or later.
– Prader-Willi syndrome (PWS), for development of growth and body composition. The diagnosis of PWS should be confirmed by suitable genetic testing.
– Replacement treatment in grown-ups with articulated growth hormone deficiency.
– Adult beginning: Patients who have severe growth hormone deficiency related with multiple hormone deficiencies because of known hypothalamic or pituitary pathology, and who have at least one known deficiency hormone not being prolactin. These patients should go through a suitable powerful test to analyze or exclude a growth hormone deficiency.
– Childhood beginning: Patients who were growth hormone deficient youth because of intrinsic, hereditary, obtained, or idiopathic causes. Patients with youth beginning GHD should be reconsidered for development chemical secretory limit after finishing of longitudinal growth. In patients with a high probability for persistent GHD, for example an innate reason or GHD optional to a hypothalamic-pituitary infection or insult, an insulin-like development factor-I (IGF-I) SDS < – 2 off growth hormone treatment for at at least 4 weeks should be viewed as sufficient evidence of profound GHD.
Any remaining patients will require IGF-I measure and one growth hormone stimulation test.
Posology and strategy for administration
Conclusion and treatment with Somatropin should be started and checked by doctors who are fittingly qualified and experienced in the finding and the board of patients with development problems.
Use and store
TOP out of the reach of children. Do not keep expired medicines or medicines that are no longer needed. Ask your healthcare professional what to do with any unused medicines. Store this medicine in the refrigerator away from direct light. Do not freeze or shake. Store the unopened Norditropin® FlexPro pen in the refrigerator away from direct light. Don’t freeze. You can also store the opened Norditropin FlexPro pen in the refrigerator for up to 4 weeks or at room temperature for up to 3 weeks. Place the used needle in a hard, airtight container that cannot be pierced by the needle. Keep this container out of reach of children and pets.
How should I use this medication?
Your doctor will determine the appropriate dose of somatropin to be injected.
Somatropin is administered by injection only. It is usually injected subcutaneously (under the skin) in the thigh, buttocks, or abdomen. It is important to rotate the site of injection in order to minimize the risk of fat wasting at the site of injection.
If you are using this medication at home, your doctor will ensure that you understand exactly how to use it. Make sure you ask any and all questions necessary to ensure that you use it exactly as prescribed. Please refer to the appropriate package insert for details on how to mix the medicine and for proper injection procedures. It is important to visit your doctor regularly during therapy to ensure that the medication is working safely and effectively.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important to use this medication exactly as prescribed by your doctor. If you miss a dose of the medicine, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Somatropin vials and pen cartridges should be refrigerated, protected from light, and kept from freezing. After the first injection, the cartridge is stable for up to 28 days provided that it is stored in a refrigerator. Leave the cartridge in the pen injector. Do not use the solution if it is discoloured or contains particles.
Keep this medication out of the reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
What Are The Possible Side Effects With This Medication?
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes this medication. If you are concerned about side effects, discuss the risks and benefits of this medication with your doctor.
The following side effects have been reported by at least 1% of people taking this medication. Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
- carpal tunnel syndrome
- joint pain
- muscle pain
- pain and swelling at site of injection
- swelling of hands, feet, or lower legs
- unusual tiredness or weakness
Although most of the side effects listed below don’t happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
- a limp
- numbness, tingling or pain in the arms, legs or face
- pain in hip or knee
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of hypothyroidism (e.g., constipation, dry skin, cold intolerance, weight gain)
- skin rash or itching
- symptoms of high blood sugar (e.g., frequent urination, increased thirst, excessive eating, unexplained weight loss, poor wound healing, infections, fruity breath odour)
- vision problems.
Stop taking the medication and seek immediate medical attention if any of the following occur:
- severe or frequent headaches with nausea and vomiting or vision problems
- signs of pancreatitis (e.g., abdominal pain on the upper left side, back pain, nausea, fever, chills, rapid heartbeat, swollen abdomen)
- signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat).
The posology and organization timetable should be individualized.
Growth disturbance because of deficient emission of development chemical in pediatric patients
By and large a dose of 0.025 – 0.035 mg/kg body weight each day or 0.7 – 1.0 mg/m2 body surface region each day is suggested. Considerably higher dosages have been used.
Where youth beginning GHD perseveres into adolescence, treatment should be kept on accomplishing full physical turn of events (for example body composition, bone mass). For observing, the fulfillment of a typical pinnacle bone mass characterized as a T score > – 1 (for example normalized to average grown-up top bone mass estimated by double energy X-beam absorptiometry considering sex and identity) is one of the restorative targets during the change time frame. For direction on dosing see grown-up segment underneath.
Prader-Willi disorder, for development of development and body composition in pediatric patients
By and large a dose of 0.035 mg/kg body weight each day or 1.0 mg/m2 body surface region each day is suggested. Day by day dosages of 2.7 mg ought not be surpassed. Treatment ought not be utilized in pediatric patients with a development speed under 1 cm each year and close to conclusion of epiphyses.
Growth Development disturbance influence because of Turner syndrome
A dose of 0.045 – 0.050 mg/kg body weight each day or 1.4 mg/m2 body surface region each day is suggested.
Growth Development influence in chronic renal insufficiency
A dose of 0.045 – 0.050 mg/kg body weight each day (1.4 mg/m2 body surface region each day) is suggested. Higher doses might be required if development speed is excessively low. A dose rectification can be required following a half year of treatment.
Growth disturbance influence in short youngsters/teenagers conceived little for gestational age (SGA)
A dose of 0.035 mg/kg body weight each day (1 mg/m2 body surface region each day) is typically suggested until conclusive stature is reached. Treatment should be stopped after the main year of treatment if the tallness speed SDS is beneath + 1. Treatment ought to be ended if stature speed is < 2 cm/year and, if confirmation is required, bone age is > 14 years (young ladies) or > 16 years (young men), comparing to conclusion of the epiphyseal development plates.